JP2023508360A5 - - Google Patents
Info
- Publication number
- JP2023508360A5 JP2023508360A5 JP2022538719A JP2022538719A JP2023508360A5 JP 2023508360 A5 JP2023508360 A5 JP 2023508360A5 JP 2022538719 A JP2022538719 A JP 2022538719A JP 2022538719 A JP2022538719 A JP 2022538719A JP 2023508360 A5 JP2023508360 A5 JP 2023508360A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- approximately
- pharmaceutical composition
- antibody
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025283256A JP2026068738A (ja) | 2019-12-23 | 2025-12-26 | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962952996P | 2019-12-23 | 2019-12-23 | |
| US62/952,996 | 2019-12-23 | ||
| US202062964970P | 2020-01-23 | 2020-01-23 | |
| US62/964,970 | 2020-01-23 | ||
| PCT/US2020/066559 WO2021133776A1 (en) | 2019-12-23 | 2020-12-22 | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283256A Division JP2026068738A (ja) | 2019-12-23 | 2025-12-26 | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508360A JP2023508360A (ja) | 2023-03-02 |
| JP2023508360A5 true JP2023508360A5 (enExample) | 2023-12-28 |
Family
ID=74191948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538719A Pending JP2023508360A (ja) | 2019-12-23 | 2020-12-22 | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 |
| JP2025283256A Pending JP2026068738A (ja) | 2019-12-23 | 2025-12-26 | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025283256A Pending JP2026068738A (ja) | 2019-12-23 | 2025-12-26 | Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230340101A1 (enExample) |
| EP (1) | EP4081544A1 (enExample) |
| JP (2) | JP2023508360A (enExample) |
| KR (1) | KR20220119446A (enExample) |
| CN (1) | CN115151568A (enExample) |
| AU (1) | AU2020415382A1 (enExample) |
| BR (1) | BR112022011388A2 (enExample) |
| CA (1) | CA3162507A1 (enExample) |
| IL (1) | IL294066A (enExample) |
| MX (1) | MX2022007958A (enExample) |
| WO (1) | WO2021133776A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| CA3236201A1 (en) * | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33) |
| KR20250017964A (ko) * | 2023-07-28 | 2025-02-04 | 재단법인 아산사회복지재단 | 혈액 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도 |
| WO2025088063A2 (en) * | 2023-10-24 | 2025-05-01 | Sanofi | Systems and methods for monitoring a medicament dosing schedule |
| CN117949666B (zh) * | 2024-01-12 | 2025-07-15 | 首都医科大学附属北京同仁医院 | 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| NZ609557A (en) | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| AR108263A1 (es) * | 2016-05-03 | 2018-08-01 | Bayer Pharma AG | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo |
| HUE067888T2 (hu) * | 2016-09-01 | 2024-11-28 | Regeneron Pharma | Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával |
| TWI784988B (zh) * | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| BR112022000740A2 (pt) * | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
-
2020
- 2020-12-22 EP EP20842863.1A patent/EP4081544A1/en active Pending
- 2020-12-22 KR KR1020227025216A patent/KR20220119446A/ko active Pending
- 2020-12-22 MX MX2022007958A patent/MX2022007958A/es unknown
- 2020-12-22 WO PCT/US2020/066559 patent/WO2021133776A1/en not_active Ceased
- 2020-12-22 US US17/786,226 patent/US20230340101A1/en active Pending
- 2020-12-22 JP JP2022538719A patent/JP2023508360A/ja active Pending
- 2020-12-22 CN CN202080096917.XA patent/CN115151568A/zh active Pending
- 2020-12-22 BR BR112022011388A patent/BR112022011388A2/pt unknown
- 2020-12-22 CA CA3162507A patent/CA3162507A1/en active Pending
- 2020-12-22 AU AU2020415382A patent/AU2020415382A1/en active Pending
-
2022
- 2022-06-19 IL IL294066A patent/IL294066A/en unknown
-
2025
- 2025-12-26 JP JP2025283256A patent/JP2026068738A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023508360A5 (enExample) | ||
| Burrage et al. | Immunomodulatory drugs in the management of SARS-CoV-2 | |
| Ji et al. | T-helper cells and their cytokines in pathogenesis and treatment of asthma | |
| Tanaka et al. | Interleukin (IL-6) immunotherapy | |
| Tan et al. | Novel biologicals for the treatment of allergic diseases and asthma | |
| Kelly et al. | Host immune responses to rhinovirus: mechanisms in asthma | |
| Busse et al. | Holy Grail: the journey towards disease modification in asthma | |
| Mitchell et al. | Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma | |
| Fu et al. | Effects of overexpression of IL-10, IL-12, TGF-β and IL-4 on allergen induced change in bronchial responsiveness | |
| Niessen et al. | T2-low: what do we know?: past, present, and future of biologic therapies in noneosinophilic asthma | |
| Lin et al. | Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis–A three-year study in Taiwan | |
| US20050244412A1 (en) | Method and composition for regulating activity of regulatory T cells | |
| Seluk et al. | Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma | |
| CN109641064A (zh) | 非整合病毒递送系统及其相关方法 | |
| Gialouri et al. | Choosing the appropriate target for the treatment of psoriatic arthritis: TNFα, IL-17, IL-23 or JAK inhibitors? | |
| JP2017537973A5 (enExample) | ||
| Chamoun et al. | Bacterial pathogenesis and interleukin-17: interconnecting mechanisms of immune regulation, host genetics, and microbial virulence that influence severity of infection | |
| Glanville et al. | Tbet deficiency causes T helper cell dependent airways eosinophilia and mucus hypersecretion in response to rhinovirus infection | |
| JP2025026945A5 (enExample) | ||
| TW202204626A (zh) | 用於活體內基因療法之調節方案 | |
| JP2022541191A5 (enExample) | ||
| Molinelli et al. | Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways | |
| Samitas et al. | Current update on eosinophilic lung diseases and anti-IL-5 treatment | |
| Lee et al. | Lentiviral-mediated interleukin-4 and interleukin-13 RNA interference decrease airway inflammation and hyperresponsiveness | |
| Danese et al. | Biological agents for ulcerative colitis: hypes and hopes |